Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug GMP compliance inspection.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that the company recently received a "Drug GMP Compliance Inspection Notification" (No. Su Drug Administration Drug Life Notification [2025] 214) issued by the Jiangsu Provincial Drug Administration. The company's tablet production line at the Jiangsu Lianyungang Port factory (203 workshop, tablet production line) passed the on-site inspection by the Jiangsu Provincial Drug Administration and met the requirements of the "Drug Manufacturing Quality Management Specification". The company has always adhered to the business philosophy of "leading in time, leading in technology", and has built technology superiority exponentially. The passing of the tablet production line in the GMP compliance inspection further strengthens the company's production and quality system for formulated products, providing a solid guarantee for the company's continuous expansion in the formulation market and having positive significance for the company's future development.